Rhumbline Advisers Insmed Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Insmed Inc stock. As of the latest transaction made, Rhumbline Advisers holds 288,337 shares of INSM stock, worth $22.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
288,337
Previous 263,045 9.62%
Holding current value
$22.7 Million
Previous $19.2 Million 3.67%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
BUY
$66.29 - $76.63 $1.68 Million - $1.94 Million
25,292 Added 9.62%
288,337 $19.9 Million
Q3 2024

Nov 12, 2024
BUY
$62.0 - $79.01 $1.64 Million - $2.1 Million
26,518 Added 11.21%
263,045 $19.2 Million
Q2 2024

Aug 01, 2024
BUY
$22.0 - $69.71 $635,030 - $2.01 Million
28,865 Added 13.9%
236,527 $15.8 Million
Q1 2024

May 09, 2024
BUY
$25.72 - $29.94 $102,005 - $118,742
3,966 Added 1.95%
207,662 $5.63 Million
Q4 2023

Feb 08, 2024
BUY
$23.42 - $31.74 $141,761 - $192,122
6,053 Added 3.06%
203,696 $6.31 Million
Q3 2023

Nov 09, 2023
BUY
$19.86 - $26.93 $81,048 - $109,901
4,081 Added 2.11%
197,643 $4.99 Million
Q2 2023

Aug 08, 2023
BUY
$16.44 - $21.1 $96,831 - $124,279
5,890 Added 3.14%
193,562 $4.08 Million
Q1 2023

May 11, 2023
BUY
$16.26 - $21.73 $86,291 - $115,321
5,307 Added 2.91%
187,672 $3.2 Million
Q4 2022

Feb 14, 2023
BUY
$16.98 - $23.15 $377,872 - $515,180
22,254 Added 13.9%
182,365 $3.64 Million
Q3 2022

Nov 10, 2022
BUY
$20.88 - $28.21 $289,647 - $391,329
13,872 Added 9.49%
160,111 $3.45 Million
Q2 2022

Aug 11, 2022
BUY
$17.07 - $25.71 $315,146 - $474,658
18,462 Added 14.45%
146,239 $2.88 Million
Q1 2022

May 12, 2022
BUY
$20.42 - $28.13 $116,863 - $160,987
5,723 Added 4.69%
127,777 $3 Million
Q4 2021

Feb 10, 2022
SELL
$25.89 - $33.45 $10,563 - $13,647
-408 Reduced 0.33%
122,054 $3.33 Million
Q3 2021

Nov 12, 2021
BUY
$22.46 - $29.47 $148,258 - $194,531
6,601 Added 5.7%
122,462 $3.37 Million
Q2 2021

Aug 05, 2021
SELL
$24.17 - $36.01 $108,015 - $160,928
-4,469 Reduced 3.71%
115,861 $3.3 Million
Q1 2021

May 06, 2021
SELL
$32.28 - $44.3 $465,994 - $639,514
-14,436 Reduced 10.71%
120,330 $4.1 Million
Q4 2020

Feb 10, 2021
BUY
$31.45 - $40.54 $133,631 - $172,254
4,249 Added 3.26%
134,766 $4.49 Million
Q3 2020

Nov 12, 2020
SELL
$26.0 - $34.5 $770,770 - $1.02 Million
-29,645 Reduced 18.51%
130,517 $4.2 Million
Q2 2020

Aug 13, 2020
BUY
$14.11 - $29.42 $454,200 - $947,029
32,190 Added 25.15%
160,162 $4.41 Million
Q1 2020

May 06, 2020
BUY
$13.63 - $33.98 $37,659 - $93,886
2,763 Added 2.21%
127,972 $2.05 Million
Q4 2019

Feb 05, 2020
BUY
$16.12 - $24.98 $135,085 - $209,332
8,380 Added 7.17%
125,209 $2.99 Million
Q3 2019

Oct 23, 2019
BUY
$15.49 - $25.78 $114,765 - $191,004
7,409 Added 6.77%
116,829 $2.06 Million
Q2 2019

Aug 14, 2019
BUY
$23.0 - $32.19 $156,584 - $219,149
6,808 Added 6.63%
109,420 $2.8 Million
Q1 2019

May 01, 2019
SELL
$13.91 - $31.15 $1,669 - $3,738
-120 Reduced 0.12%
102,612 $2.98 Million
Q4 2018

Jan 31, 2019
BUY
$11.6 - $18.7 $380,630 - $613,603
32,813 Added 46.93%
102,732 $1.35 Million
Q3 2018

Nov 07, 2018
SELL
$18.95 - $28.08 $91,718 - $135,907
-4,840 Reduced 6.47%
69,919 $1.41 Million
Q2 2018

Aug 06, 2018
BUY
$20.0 - $29.72 $30,800 - $45,768
1,540 Added 2.1%
74,759 $1.77 Million
Q1 2018

May 02, 2018
SELL
$21.69 - $32.99 $29,389 - $44,701
-1,355 Reduced 1.82%
73,219 $1.65 Million
Q4 2017

Feb 09, 2018
SELL
$26.43 - $31.78 $285,391 - $343,160
-10,798 Reduced 12.65%
74,574 $2.33 Million
Q3 2017

Nov 06, 2017
BUY
$11.61 - $31.21 $991,168 - $2.66 Million
85,372
85,372 $2.66 Million

Others Institutions Holding INSM

# of Institutions
484
Shares Held
187M
Call Options Held
2.15M
Put Options Held
3.22M
View Full List

About INSMED Inc

INSM Quotes by TradingView
  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10.7B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email